Menu

Azuvas

CAD

Non-Modifiable Risk factors:

  • Age  (incidence of  CAD  increases with age)
  • Sex  ( Males >  females)
  • Family  history
  • Genetic  factors  and  Personality
  • People with type A  personality  are
  • more  prone  to develop CAD)

CAD Modifiable risk factors

(1) Non-lipid risk factors :

  • High  blood  pressure
  • Diabetes
  • Obesity
  • Sedentary  life style
  • Stress
  • Smoking

(2) Lipid risk factors :

  • Total cholesterol  (TC) : >200mg/dl
  • Low  Density  Lipoprotein (LDL) : >100mg/dl
  • Triglyceride (TG): > 150mg/dl.
  • High  Density  Lipoprotein (HDL): <40mg/dl

Lipid – Lowering Drugs

  • HMG –CoA reductase inhibitors (statins) - Rosuvastatin ,atorvastatin, simvastatin,pitavastatin
  • Fibric acid derivatives (Fibrates) –
    • Fenofibrate, gemfibrozil, bezafibrate,
  • Selective cholesterol absorption inhibitors:
    • Ezetimibe
  • Nicotinic acid
  • Bile- acid binding resins

Fenofibrate – Non- Lipid Actions

  • Reduction in serum uric acid levels
  • Lowering of serum fibrinogen levels
  • Fenofibrate improves insulin sensitivity

Azuvas 10 F : Indications

  • Combined/mixed hyperlipidemia
  • Diabetic Dyslipidemia
  • Patients with CAD not able to achieve goals of therapy with statin monotherapy

Azuvas 10 F : Dosage

  • The recommended dosage is one tablet, once daily either morning or evening
  • should be given with meals, thereby optimizing the bioavailability of Fenofibrate

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Azuvas (Rosuvastatin) 10,20,40 mg

Rosuvastatin Mechanism of Action

HMG – COA

HMG – COA Reductase XRosuvastatin

Mevalonate

Cholesterol

Rosuvastatin Lipid actions

  • Decreases synthesis of cholesterol in the liver - by inhibiting HMG Co-A Reductase enzyme
  • Other Lipid actions:
    • Lowering of LDL-C by upto 52%
    • Lowering triglycerides by upto 37%
    • Lowering of total cholesterol by upto 36 %
    • Increase in HDL-C levels upto 14%

Rosuvastatin Target Population

  • Patients with CAD-Primary & Secondary prevention
  • Patients with Diabetes
  • Patients with Stroke/TIA
  • Patients with 2 or more major risk factors for CAD (smokers, men>45, hypertension, HDL-

Rosuvastatin - Dose

  • Recommended starting dose of Rosuvastatin is 10 mg once daily
  • For patients with marked hyperlipedemia (LDL – C > 190 mg/dL) and aggressive lipid targets, a 20 mg starting dose may be considered

Once Daily, with or without food, Any time of the Day